We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+3.48%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$942M
AUM Growth
+$47.5M
(+5.3%)
Cap. Flow
+$57.7M
Cap. Flow
% of AUM
6.13%
Top 10 Holdings %
Top 10 Hldgs %
36.92%
Holding
174
New
107
Increased
33
Reduced
23
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$22.8M |
| 2 |
FOLD
Amicus Therapeutics
FOLD
|
+$16.4M |
| 3 |
Collegium Pharmaceutical
COLL
|
+$15.5M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$13.7M |
| 5 |
AERI
Aerie Pharmaceuticals
AERI
|
+$10.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$24.4M |
| 2 |
Molina Healthcare
MOH
|
+$17.5M |
| 3 |
EXAS
Exact Sciences
EXAS
|
+$14.2M |
| 4 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$13.9M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$11.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.63% |
| 2 | Industrials | 0.89% |
| 3 | Technology | 0.84% |
| 4 | Financials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
| $58.8M | 6.25% |
4,867,290
+1,173,600
| +32% | +$16.4M |
|
|
AERI
2
DELISTED
Aerie Pharmaceuticals
AERI
| $47.9M | 5.08% |
777,470
+161,600
| +26% | +$10.4M |
|
|
APLS
3
DELISTED
Apellis Pharmaceuticals
APLS
| $36.2M | 3.85% |
2,038,516
+295,894
| +17% | +$5.47M |
|
4
Alnylam Pharmaceuticals
ALNY
$35.7B
| $33.6M | 3.57% |
384,041
+80,341
| +26% | +$8.08M |
|
|
LJPC
5
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $33.2M | 3.52% |
1,648,772
+335,667
| +26% | +$8.77M |
|
|
ARRY
6
DELISTED
Array Biopharma Inc
ARRY
| $31.8M | 3.38% |
2,094,167
+527,690
| +34% | +$8.09M |
|
|
7
Collegium Pharmaceutical
COLL
$1.17B
| $29.3M | 3.11% |
1,989,455
+876,322
| +79% | +$15.5M |
|
8
Teladoc Health
TDOC
$1.7B
| $26.9M | 2.86% |
311,821
-161,208
| -34% | -$11.5M |
|
|
CELG
9
DELISTED
Celgene Corp
CELG
| $25.1M | 2.67% |
281,012
+257,800
| +1,111% | +$22.8M |
|
|
KTWO
10
DELISTED
K2M Group Holdings, Inc
KTWO
| $24.8M | 2.63% |
906,741
-44,046
| -5% | -$1.03M |
|
|
EXAS
11
DELISTED
Exact Sciences
EXAS
| $20.6M | 2.19% |
261,050
-217,599
| -45% | -$14.2M |
|
12
Gilead Sciences
GILD
$167B
| $20.5M | 2.18% |
266,140
+1,940
| +0.7% | +$147K |
|
|
PTLA
13
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $19.8M | 2.11% |
744,607
-50,655
| -6% | -$1.65M |
|
14
Pfizer
PFE
$143B
| $19.8M | 2.11% |
474,222
-42,581
| -8% | -$1.64M |
|
15
Novartis
NVS
$293B
| $19.6M | 2.08% |
253,495
+2,790
| +1% | +$206K |
|
16
Johnson & Johnson
JNJ
$609B
| $19.2M | 2.04% |
139,280
-900
| -0.6% | -$120K |
|
|
ADMS
17
DELISTED
Adamas Pharmaceuticals
ADMS
| $18.1M | 1.92% |
903,424
+367,904
| +69% | +$8.64M |
|
18
BioMarin Pharmaceuticals
BMRN
$11.5B
| $17.9M | 1.9% |
184,695
-75,810
| -29% | -$7.57M |
|
|
XLRN
19
DELISTED
Acceleron Pharma
XLRN
| $17.1M | 1.82% |
298,726
-7,900
| -3% | -$388K |
|
|
IMMU
20
DELISTED
Immunomedics Inc
IMMU
| $16.1M | 1.71% |
771,307
+75,572
| +11% | +$1.79M |
|
21
Evolent Health
EVH
$654M
| $16M | 1.7% |
564,203
+95,321
| +20% | +$2.27M |
|
22
UnitedHealth
UNH
$387B
| $15.4M | 1.63% |
57,805
-3,970
| -6% | -$1.03M |
|
23
Bristol-Myers Squibb
BMY
$124B
| $14.9M | 1.59% |
240,697
+46,308
| +24% | +$2.75M |
|
|
24
Vertex Pharmaceuticals
VRTX
$123B
| $14.8M | 1.57% |
+76,846
| New | +$13.7M |
|
25
iRhythm Holdings
IRTC
$3.64B
| $13.7M | 1.45% |
144,700
| – | – |
|
Similar funds
RIP
CCM
LFWA
FWA
CF
WIM
MW
AFC
Sectoral Asset Management's Q3 2018 Portfolio in Review
As of Q3 2018, Sectoral Asset Management held 174 positions worth $942M, up 5.3% from $894M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Sectoral Asset Management deployed $57.7M of net new capital in Q3 2018, opening 107 new positions and adding to 33 existing holdings. Its largest new stake was Vertex Pharmaceuticals: 76,846 shares worth $14.8M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 85% a quarter earlier, followed by Industrials and Technology.
On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $24.4M trimmed.
- Sectoral Asset Management's largest Q3 2018 buy was Vertex Pharmaceuticals: 76,846 shares worth $14.8M.
- Sectoral Asset Management added most to Celgene Corp in Q3 2018, an estimated $22.8M increase.
- Sectoral Asset Management's biggest Q3 2018 reduction was Sarepta Therapeutics, cutting an estimated $24.4M.
- Sectoral Asset Management fully exited Molina Healthcare in Q3 2018, selling an estimated $17.5M.
- Sectoral Asset Management's ten largest holdings make up 37% of its $942M portfolio in Q3 2018.
- Sectoral Asset Management opened 107 new positions and closed 6 in Q3 2018.
- Sectoral Asset Management's portfolio value rose 5.3% quarter-over-quarter to $942M.
Based on Sectoral Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.